Merck Launches National Advertising Campaign for GARDASIL(R), Merck's New Cervical Cancer Vaccine.

Campaign Highlights the Value of Vaccination and the Continued Importance of Screening

WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. announced today the launch of a national print, television and online advertising campaign for the worldeIUs first cervical cancer vaccine, GARDASIL(E1/2) [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine]. GARDASIL was approved by the FDA on June 8 eI and provisionally recommended by the Advisory Committee on Immunization Practices (ACIP) on June 29 eI for girls and women aged 9-261. GARDASIL is the worldeIUs first and only vaccine indicated for the prevention of HPV types 16- and 18-related cervical cancer, cervical pre-cancers (CIN 2/3 and AIS), vulvar pre-cancers (VIN 2/3) and vaginal pre-cancers (VaIN 2/3) and for the prevention of genital warts and low-grade cervical lesions (CIN 1) caused by HPV types 6, 11, 16 and 18. Adding to Merck's ongoing cervical cancer and HPV education efforts, the new campaign, called One Less, encourages females who are eligible for the vaccine to begin their vaccination series and to also continue to see their doctor for regular healthcare and screening.

"The full public health benefit of reducing the burden of cervical cancer and HPV disease may be achieved through broad public awareness and vaccination with GARDASIL, which is the driving force behind One Less," said Bev Lybrand, vice president & general manager, HPV Franchise, GARDASIL, Merck Vaccine Division. "Merck is committed to educating and providing access to women and girls who may benefit from this critical vaccine."

One Less is the continuation of Merck's commitment to disease and vaccine education. GARDASIL is for girls and women ages 9-26 years of age. If these girls and women have already been infected with HPV, they may still benefit from GARDASIL because it is unlikely that they have been infected with all four types of the virus covered by the vaccine. To inform and encourage these girls and women, the campaign focuses on a strong and positive message that is designed to empower them to want to become (or help their daughters want to become) "one less" person who will battle cervical cancer.

The campaign also focuses on important information about GARDASIL. GARDASIL may not fully protect everyone, and GARDASIL does not prevent all types of cervical cancer, so ongoing cervical cancer screenings will be important. GARDASIL is not recommended for use in pregnant women and GARDASIL will not treat cervical cancer. GARDASIL can cause injection site-pain, -swelling, -itching and -redness as well as fever, dizziness or nausea. For more information about this campaign and to view the commercials, visit www.gardasil.com.

Committed to public awareness

In addition to One Less, Merck will continue to separately support HPV disease education including the Tell Someone and the Make the Connection multi-lingual disease awareness programs to ensure an understanding about the important link between cervical cancer and HPV and the need to continue regular screening. Merck also provides support and grant funding to national and local organizations to help disseminate disease information to broad and diverse audiences, including those with outreach to underserved communities.

Access to GARDASIL

There is broad private and public coverage for GARDASIL. Health insurers covering approximately 94 percent of privately insured lives in the U.S. (currently more than 100 insurance plans) have decided to reimburse GARDASIL. GARDASIL was added to the Vaccines for Children (VFC) Program on November 1. Many lives not covered by Managed Care will now be covered under the VFC Program. Merck has also initiated a new patient assistance program for vaccines. Through this new program, currently available in private physicians' offices and private clinics, Merck is making available, free of charge, GARDASIL and other Merck vaccines indicated for use in individuals aged 19 and older who are uninsured and who are unable to afford vaccines.

Merck is also actively working to accelerate the availability of GARDASIL in the developing world: Merck is working with PATH to develop HPV vaccination programs that will facilitate the introduction of GARDASIL to the most impoverished nations. This initiative is funded by a grant to PATH from the Bill & Melinda Gates Foundation. Merck has also announced a partnership with India's Council of Medical Research to study GARDASIL. Merck will make our new vaccines, including GARDASIL, available at dramatically lower prices to developing world countries.

Dosage and administration for GARDASIL

GARDASIL is a ready-to-use, three-dose, intramuscular vaccine. GARDASIL should be administered in three separate intramuscular injections in the upper arm or upper thigh over a six-month period. The following dosage schedule is recommended: first dose at elected date, second dose two months after the first dose and the third dose six months after the first dose.

Selected important information about GARDASIL

GARDASIL is contraindicated in individuals who are hypersensitive to the active substances or to any of the excipients of the vaccine.

The health-care provider should inform the patient, parent or guardian that vaccination does not substitute for routine cervical cancer screening. Women who receive GARDASIL should continue to undergo cervical cancer screening per standard of care.

Vaccination with GARDASIL may not result in protection in all vaccine recipients. GARDASIL is not intended to be used for treatment of active genital warts; cervical cancer; CIN, VIN, or VaIN. GARDASIL has not been shown to protect against disease due to non-vaccine HPV types.

Vaccine-related adverse experiences that were observed in clinical trials at a frequency of at least 1.0 percent among recipients of GARDASIL and also greater than those observed among recipients of placebo, respectively, were pain (83.9 percent vs. 75.4 percent), swelling (25.4 percent vs. 15.8 percent), erythema (24.6 percent vs. 18.4 percent), fever (10.3 percent vs. 8.6 percent), nausea (4.2 percent vs. 4.1 percent), pruritis (3.1 percent vs. 2.8 percent) and dizziness (2.8 percent vs. 2.6 percent).

About HPV disease

In the United States, approximately 20 million people are infected with HPV, and approximately 80 percent of females will have acquired HPV by age 50. For most people, HPV goes away on its own; however in some, certain high-risk types of HPV, if unrecognized and untreated, can lead to cervical cancer. Cervical cancer is the second most common cause of cancer death in women worldwide, resulting in nearly a half-million diagnoses and 240,000 deaths each year. It is estimated that in 2006, there will be approximately 9,700 new cases of cervical cancer and 3,700 deaths in the United States. In addition, certain low-risk types of HPV cause genital warts and can lead to abnormal Pap results. Approximately one million cases of genital warts occur each year in the United States and an estimated 32 million cases occur worldwide. HPV types 16 and 18 account for approximately 70 percent of cases of cervical cancer, AIS (non-invasive cervical cancer), CIN 3, VIN 2/3 and VaIN 2/3, and account for 50 percent of CIN 2 lesions. HPV 6 and 11 cause approximately 90 percent of genital wart cases. These four types of HPV also cause approximately 35 to 50 percent of all low-grade cervical, vaginal and vulvar lesions (CIN I, VIN I and VaIN I). Additionally, there are an estimated 4.7 million abnormal Pap results that require follow-up each year in the United States. At least 3 million of these results are caused by some type of HPV.

Worldwide availability of GARDASIL

GARDASIL has been approved in more than 40 countries including the European Union, Mexico, Australia, Taiwan, Canada, New Zealand and Brazil. Additional applications for GARDASIL are currently under review with regulatory agencies in more than 50 countries around the world.

Other Information about GARDASIL

In 1995, Merck entered into a license agreement and collaboration with CSL Limited relating to technology used in GARDASIL. GARDASIL also is the subject of other third-party licensing agreements.

About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.

Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2005, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference.

Prescribing information and patient product information for GARDASIL(E1/2) is attached and is also available at www.gardasil.com.

1 The ACIP recommended that GARDASIL be administered to 11- and 12- year-old females and to females aged 13 to 26 who have not previously been vaccinated, and that nine- and 10-year-old females can be vaccinated with GARDASIL at the discretion of their physicians.

GARDASIL(E1/2) is a registered trademark of Merck & Co., Inc, Whitehouse Station, N.J., U.S.A.

GARDASIL(R)                                                    9682302
(Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18)
Recombinant Vaccine)

   DESCRIPTION

   GARDASIL* is a non-infectious recombinant, quadrivalent vaccine
prepared from the highly purified virus-like particles (VLPs) of the
major capsid (L1) protein of HPV Types 6, 11, 16, and 18. The L1
proteins are produced by separate fermentations in recombinant
Saccharomyces cerevisiae and self-assembled into VLPs. The
fermentation process involves growth of S. cerevisiae on
chemically-defined fermentation media which include vitamins, amino
acids, mineral salts, and carbohydrates. The VLPs are released from
the yeast cells by cell disruption and purified by a series of
chemical and physical methods. The purified VLPs are adsorbed on
preformed aluminum-containing adjuvant (amorphous aluminum
hydroxyphosphate sulfate). The quadrivalent HPV VLP vaccine is a
sterile liquid suspension that is prepared by combining the adsorbed
VLPs of each HPV type and additional amounts of the
aluminum-containing adjuvant and the final purification buffer.

   GARDASIL is a sterile preparation for intramuscular
administration. Each 0.5-mL dose contains approximately 20 mcg of HPV
6 L1 protein, 40 mcg of HPV 11 L1 protein, 40 mcg of HPV 16 L1
protein, and 20 mcg of HPV 18 L1 protein.

   Each 0.5-mL dose of the vaccine contains approximately 225 mcg of
aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant),
9.56 mg of sodium chloride, 0.78 mg of L-histidine, 50 mcg of
polysorbate 80, 35 mcg of sodium borate, and water for injection. The
product does not contain a preservative or antibiotics.

   After thorough agitation, GARDASIL is a white, cloudy liquid.

   CLINICAL PHARMACOLOGY

   Disease Burden

   Human Papillomavirus (HPV) causes squamous cell cervical cancer
(and its histologic precursor lesions Cervical Intraepithelial
Neoplasia (CIN) 1 or low grade dysplasia and CIN 2/3 or moderate to
high grade dysplasia) and cervical adenocarcinoma (and its precursor
lesion adenocarcinoma in situ (AIS)). HPV also causes approximately
35-50% of vulvar and vaginal cancers. Vulvar Intraepithelial Neoplasia
(VIN) Grade 2/3 and Vaginal Intraepithelial Neoplasia (VaIN) Grade 2/3
are immediate precursors to these cancers.

   Cervical cancer prevention focuses on routine screening and early
intervention. This strategy has reduced cervical cancer rates by
approximately 75% in compliant individuals by monitoring and removing
premalignant dysplastic lesions.

   HPV also causes genital warts (condyloma acuminata) which are
growths of the cervicovaginal, vulvar, and the external genitalia that
rarely progress to cancer. HPV 6, 11, 16, and 18 are common HPV types.

   HPV 16 and 18 cause approximately:

   --  70% of cervical cancer, AIS, CIN 3, VIN 2/3, and VaIN 2/3
        cases; and

   --  50% of CIN 2 cases.

   HPV 6, 11, 16, and 18 cause approximately:

   --  35 to 50% of all CIN 1, VIN 1, and VaIN 1 cases; and

   --  90% of genital wart cases.

   Mechanism of Action

   HPV only infects humans, but animal studies with analogous
(animal, not human) papillomaviruses suggest that the efficacy of L1
VLP vaccines is mediated by the development of humoral immune
responses.

   CLINICAL STUDIES

   CIN 2/3 and AIS are the immediate and necessary precursors of
squamous cell carcinoma and adenocarcinoma of the cervix,
respectively. Their detection and removal has been shown to prevent
cancer; thus, they serve as surrogate markers for prevention of
cervical cancer.

   Efficacy was assessed in 4 placebo-controlled, double-blind,
randomized Phase II and III clinical studies. The first Phase II study
evaluated the HPV 16 component of GARDASIL (Protocol 005, N = 2391)
and the second evaluated all components of GARDASIL (Protocol 007, N =
551). The Phase III studies, termed FUTURE (Females United To
Unilaterally Reduce Endo/Ectocervical Disease), evaluated GARDASIL in
5442 (FUTURE I or Protocol 013) and 12,157 (FUTURE II or Protocol 015)
subjects. Together, these four studies evaluated 20,541 women 16 to 26
years of age at enrollment. The median duration of follow-up was 4.0,
3.0, 2.4, and 2.0 years for Protocol 005, Protocol 007, FUTURE I, and
FUTURE II, respectively. Subjects received vaccine or placebo on the
day of enrollment, and 2 and 6 months thereafter. Efficacy was
analyzed for each study individually and for all studies combined
according to a prospective clinical plan.

   Prophylactic Efficacy

   GARDASIL is designed to prevent HPV 6-, 11-, 16-, and/or
18-related cervical cancer, cervical dysplasias, vulvar or vaginal
dysplasias, or genital warts. GARDASIL was administered without
prescreening for presence of HPV infection and the efficacy trials
allowed enrollment of subjects regardless of baseline HPV status
(i.e., Polymerase Chain Reaction (PCR) status or serostatus). Subjects
who were infected with a particular vaccine HPV type (and who may
already have had disease due to that infection) were not eligible for
prophylactic efficacy evaluations for that type.

   The primary analyses of efficacy were conducted in the
per-protocol efficacy (PPE) population, consisting of individuals who
received all 3 vaccinations within 1 year of enrollment, did not have
major deviations from the study protocol, and were naive (PCR negative
in cervicovaginal specimens and seronegative) to the relevant HPV
type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month
Postdose 3 (Month 7). Efficacy was measured starting after the Month 7
visit.

   Overall, 73% of subjects were naive (i.e., PCR negative and
seronegative for all 4 vaccine HPV types) to all 4 vaccine HPV types
at enrollment.

   A total of 27% of subjects had evidence of prior exposure to or
ongoing infection with at least 1 of the 4 vaccine HPV types. Among
these subjects, 74% had evidence of prior exposure to or ongoing
infection with only 1 of the 4 vaccine HPV types and were naive (PCR
negative and seronegative) to the remaining 3 types.

   In subjects who were naive (PCR negative and seronegative) to all
4 vaccine HPV types, CIN, genital warts, VIN, and VaIN caused by any
of the 4 vaccine HPV types were counted as endpoints.

   Among subjects who were positive (PCR positive and/or
seropositive) for a vaccine HPV type at Day 1, endpoints related to
that type were not included in the analyses of prophylactic efficacy.
Endpoints related to the remaining types for which the subject was
naive (PCR negative and seronegative) were counted.

   For example, in subjects who were HPV 18 positive (PCR positive
and/or seropositive) at Day 1, lesions caused by HPV 18 were not
counted in the prophylactic efficacy evaluations. Lesions caused by
HPV 6, 11, and 16 were included in the prophylactic efficacy
evaluations. The same approach was used for the other types.

   GARDASIL was efficacious in reducing the incidence of CIN (any
grade including CIN 2/3); AIS; genital warts; VIN (any grade); and
VaIN (any grade) related to vaccine HPV types in those who were PCR
negative and seronegative at baseline (Table 1).



                               Table 1
      Analysis of Efficacy of GARDASIL in the PPE* Population**
----------------------------------------------------------------------
                           GARDASIL    Placebo
                          ----------------------
        Population             Number     Number % Efficacy (95% CI)
                            n    of    n    of
                                cases      cases
======================================================================
HPV 16- or 18-related CIN 2/3 or AIS
----------------------------------------------------------------------
     Protocol 005***       755     0  750    12    100.0 (65.1, 100.0)
----------------------------------------------------------------------
       Protocol 007        231     0  230     1 100.0 (-3734.9, 100.0)
----------------------------------------------------------------------
         FUTURE I         2200     0 2222    19    100.0 (78.5, 100.0)
----------------------------------------------------------------------
        FUTURE II         5301     0 5258    21  100.0+ (80.9, 100.0)
----------------------------------------------------------------------
   Combined Protocols++   8487     0 8460    53  100.0+ (92.9, 100.0)
----------------------------------------------------------------------
HPV 6-, 11-, 16-, 18-related CIN (CIN 1, CIN 2/3) or AIS
----------------------------------------------------------------------
       Protocol 007        235     0  233     3  100.0 (-137.8, 100.0)
----------------------------------------------------------------------
         FUTURE I         2240     0 2258    37  100.0+ (89.5, 100.0)
----------------------------------------------------------------------
        FUTURE II         5383     4 5370    43      90.7 (74.4, 97.6)
----------------------------------------------------------------------
    Combined Protocols    7858     4 7861    83      95.2 (87.2, 98.7)
======================================================================
HPV 6-, 11-, 16-, or 18-related Genital Warts
----------------------------------------------------------------------
       Protocol 007        235     0  233     3  100.0 (-139.5, 100.0)
----------------------------------------------------------------------
         FUTURE I         2261     0 2279    29    100.0 (86.4, 100.0)
----------------------------------------------------------------------
        FUTURE II         5401     1 5387    59     98.3 (90.2, 100.0)
----------------------------------------------------------------------
    Combined Protocols    7897     1 7899    91     98.9 (93.7, 100.0)
----------------------------------------------------------------------
* The PPE population consisted of individuals who received all 3
 vaccinations within 1 year of enrollment, did not have major
 deviations from the study protocol, and were naive (PCR negative and
 seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18)
 prior to dose 1 and through 1 month Postdose 3 (Month 7).
**See Table 2 for analysis of vaccine impact in the general
 population.
***Evaluated only the HPV 16 L1 VLP vaccine component of GARDASIL.
+P-values were computed for pre-specified primary hypothesis tests.
 All p-values were less than 0.001, supporting the following
 conclusions: efficacy against HPV 16/18-related CIN 2/3 is greater
 than 0% (FUTURE II); efficacy against HPV 16/18-related CIN 2/3 is
 greater than 25% (Combined Protocols); and efficacy against HPV
 6/11/16/18-related CIN is greater than 20% (FUTURE I).
++Analyses of the combined trials were prospectively planned and
 included the use of similar study entry criteria.
n = Number of subjects with at least 1 follow-up visit after Month 7.
Note 1: Point estimates and confidence intervals are adjusted for
 person-time of follow-up.
Note 2: The first analysis in the table (i.e., HPV 16- or 18-related
 CIN 2/3, AIS or worse) was the primary endpoint of the vaccine
 development plan.
Note 3: FUTURE I refers to Protocol 013; FUTURE II refers to Protocol
 015.
----------------------------------------------------------------------


   GARDASIL was efficacious against HPV disease caused by each of the
4 vaccine HPV types.

   In a pre-defined analysis, the efficacy of GARDASIL against HPV
16/18-related disease was 100% (95% CI: 87.9%, 100.0%) for CIN 3 or
AIS and 100% (95% CI: 55.5%, 100.0%) for VIN 2/3 or VaIN 2/3. The
efficacy of GARDASIL against HPV 6-, 11-, 16-, and 18-related VIN 1 or
VaIN 1 was 100% (95% CI: 75.8%, 100.0%). These analyses were conducted
in the PPE population that consisted of individuals who received all 3
vaccinations within 1 year of enrollment, did not have major
deviations from the study protocol, and were naive (PCR negative and
seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18)
prior to dose 1 and through 1 month Postdose 3 (Month 7).

   Efficacy in Subjects with Current or Prior Infection

   GARDASIL is a prophylactic vaccine.

   There was no clear evidence of protection from disease caused by
HPV types for which subjects were PCR positive and/or seropositive at
baseline.

   Individuals who were already infected with 1 or more
vaccine-related HPV types prior to vaccination were protected from
clinical disease caused by the remaining vaccine HPV types.

   General Population Impact

   The general population of young American women includes women who
are HPV-naive (PCR negative and seronegative) and women who are
HPV-non-naive (PCR positive and/or seropositive), some of whom have
HPV-related disease. The clinical trials population approximated the
general population of American women with respect to prevalence of HPV
infection and disease at enrollment. Analyses were conducted to
evaluate the overall impact of GARDASIL with respect to HPV 6-, 11-,
16-, and 18-related cervical and genital disease in the general
population. Here, analyses included events arising from HPV infections
that were present at the start of vaccination as well as events that
arose from infections that were acquired after the start of
vaccination.

   The impact of GARDASIL in the general population is shown in Table
2. Impact was measured starting 1 month Postdose 1. Prophylactic
efficacy denotes the vaccine's efficacy in women who are naive (PCR
negative and seronegative) to the relevant HPV types at vaccination
onset. General population impact denotes vaccine impact among women
regardless of baseline PCR status and serostatus. The majority of CIN
and genital warts, VIN, and VaIN detected in the group that received
GARDASIL occurred as a consequence of HPV infection with the relevant
HPV type that was already present at Day 1.


                               Table 2
           General Population Impact for Vaccine HPV Types
----------------------------------------------------------------------
                             GARDASIL or
                              HPV 16 L1   Placebo
                                 VLP
                               Vaccine                % Reduction
    Endpoints      Analysis  ----------------------     (95% CI)
                               N  Cases   N  Cases
======================================================================
                 Prophylactic
                   Efficacy* 9342     1 9400    81  98.8 (92.9, 100.0)
                 -----------------------------------------------------
 HPV 16- or 18-    HPV 16
 related CIN 2/3  and/or HPV
      or AIS      18 Positive
                   at Day 1    --   121   --   120                 --
                 -----------------------------------------------------
                   General
                  Population
                   Impact**  9831   122 9896   201   39.0 (23.3, 51.7)
======================================================================
                 Prophylactic
                   Efficacy* 8641     0 8667    24 100.0 (83.3, 100.0)
                 -----------------------------------------------------
 HPV 16- or 18-    HPV 16
 related VIN 2/3  and/or HPV
   and VaIN 2/3   18 Positive
                   at Day 1    --     8   --     2                 --
                 -----------------------------------------------------
                   General
                  Population
                   Impact**  8954     8 8962    26   69.1 (29.8, 87.9)
======================================================================
                 Prophylactic
                   Efficacy* 8625     9 8673   143   93.7 (87.7, 97.2)
                 -----------------------------------------------------
HPV 6-, 11-, 16-,HPV 6, HPV
 18-related CIN   11, HPV 16,
 (CIN 1, CIN 2/3) and/or HPV      161***     174***
      or AIS      18 Positive
                   at Day 1    --         --                       --
                 -----------------------------------------------------
                   General
                  Population
                   Impact**  8814   170 8846   317   46.4 (35.2, 55.7)
======================================================================
                 Prophylactic
                   Efficacy* 8760     9 8786   136   93.4 (87.0, 97.0)
                 -----------------------------------------------------
HPV 6-, 11-, 16-,HPV 6, HPV
  or 18-related   11, HPV 16,
  Genital Warts   and/or HPV                  48+
                  18 Positive
                   at Day 1    --    49   --                       --
                 -----------------------------------------------------
                   General
                  Population
                   Impact**  8954    58 8962   184   68.5 (57.5, 77.0)
----------------------------------------------------------------------
*Includes all subjects who received at least 1 vaccination and who
 were naive (PCR negative and seronegative) to HPV 6, 11, 16, and/or
 18 at Day 1. Case counting started at 1 Month Postdose 1.
**Includes all subjects who received at least 1 vaccination
 (regardless of baseline HPV status at Day 1). Case counting started
 at 1 Month Postdose 1.
***Includes 2 subjects (1 in each vaccination group) who underwent
 colposcopy for reasons other than an abnormal Pap and 1 placebo
 subject with missing serology/PCR data at day 1.
+Includes 1 subject with missing serology/PCR data at day 1.
Note 1: The 16- and 18-related CIN 2/3 or AIS composite endpoint
 included data from studies 005, 007, 013, and 015. All other
 endpoints only included data from studies 007, 013, and 015.
Note 2: Positive status at Day 1 denotes PCR positive and/or
 seropositive for the respective type at Day 1.
Note 3: Percent reduction includes the prophylactic efficacy of
 GARDASIL as well as the impact of GARDASIL on the course of
 infections present at the start of the vaccination.
Note 4: Table 2 does not include disease due to non-vaccine HPV types.
----------------------------------------------------------------------


   GARDASIL does not prevent infection with the HPV types not
contained in the vaccine. Cases of disease due to non-vaccine types
were observed among recipients of GARDASIL and placebo in Phase II and
Phase III efficacy studies.

   Among cases of CIN 2/3 or AIS caused by vaccine or non-vaccine HPV
types in subjects in the general population who received GARDASIL, 79%
occurred in subjects who had an abnormal Pap test at Day 1 and/or who
were positive (PCR positive and/or seropositive) to HPV 6, 11, 16,
and/or 18 at Day 1.

   An interim analysis of the general population impact for GARDASIL
was performed from studies 007, 013, and 015 that had a median
duration of follow-up of 1.9 years. GARDASIL reduced the overall rate
of CIN 2/3 or AIS caused by vaccine or non-vaccine HPV types by 12.2%
(95% CI: -3.2%, 25.3%), compared with placebo.

   An analysis of overall population impact for the HPV 16 L1 VLP
vaccine was conducted from study 005 that had a median duration of
follow-up of 3.9 years. The HPV 16 L1 VLP vaccine reduced the overall
incidence of CIN 2/3 caused by vaccine or non-vaccine HPV types by
32.7% (95% CI: -34.7%, 67.3%) through a median duration of follow-up
of 1.9 years (fixed case analysis) and by 45.3% (95% CI: 10.9%,
67.1%), through a median duration of follow-up of 3.9 years (end of
study).

   GARDASIL reduced the incidence of definitive therapy (e.g., loop
electrosurgical excision procedure, laser conization, cold knife
conization) by 16.5% (95% CI: 2.9%, 28.2%), and surgery to excise
external genital lesions by 26.5% (95% CI: 3.6%, 44.2%), compared with
placebo for all HPV-related diseases. These analyses were performed in
the general population of women which includes women regardless of
baseline HPV PCR status or serostatus. GARDASIL has not been shown to
protect against the diseases caused by all HPV types and will not
treat existing disease caused by the HPV types contained in the
vaccine. The overall efficacy of GARDASIL, described above, will
depend on the baseline prevalence of HPV infection related to vaccine
types in the population vaccinated and the incidence of HPV infection
due to types not included in the vaccine.

   Immunogenicity

   Assays to Measure Immune Response

   Because there were few disease cases in subjects naive (PCR
negative and seronegative) to vaccine HPV types at baseline in the
group that received GARDASIL, it has not been possible to establish
minimum anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 antibody
levels that protect against clinical disease caused by HPV 6, 11, 16,
and/or 18.

   The immunogenicity of GARDASIL was assessed in 8915 women
(GARDASIL N = 4666; placebo N = 4249) 18 to 26 years of age and female
adolescents 9 to 17 years of age (GARDASIL N = 1471; placebo N = 583).

   Type-specific competitive immunoassays with type-specific
standards were used to assess immunogenicity to each vaccine HPV type.
These assays measured antibodies against neutralizing epitopes for
each HPV type. The scales for these assays are unique to each HPV
type; thus, comparisons across types and to other assays are not
appropriate.

   Immune Response to GARDASIL

   The primary immunogenicity analyses were conducted in a
per-protocol immunogenicity (PPI) population. This population
consisted of individuals who were seronegative and PCR negative to the
relevant HPV type(s) at enrollment, remained HPV PCR negative to the
relevant HPV type(s) through 1 month Postdose 3 (Month 7), received
all 3 vaccinations, and did not deviate from the study protocol in
ways that could interfere with the effects of the vaccine.

   Overall, 99.8%, 99.8%, 99.8%, and 99.5% of girls and women who
received GARDASIL became anti-HPV 6, anti-HPV 11, anti-HPV 16, and
anti-HPV 18 seropositive, respectively, by 1 month Postdose 3 across
all age groups tested. Anti-HPV 6, anti-HPV 11, anti-HPV 16, and
anti-HPV 18 GMTs peaked at Month 7. GMTs declined through Month 24 and
then stabilized through Month 36 at levels above baseline (Table 3).
The duration of immunity following a complete schedule of immunization
with GARDASIL has not been established.


                               Table 3
Summary of Anti-HPV cLIA Geometric Mean Titers in the PPI* Population
----------------------------------------------------------------------
                                                        Aluminum-
                                  GARDASIL              Containing
                                  N** = 276               Placebo
                                                         N = 275
       Study Time        ---------------------------------------------
                              Geometric Mean Titer      Geometric Mean
                         n***        (95% CI)        n    Titer (95%
                                     mMU/mL+                  CI)
                                                            mMU/mL
======================================================================
Anti-HPV 6
----------------------------------------------------------------------
        Month 07         208    582.2 (527.2, 642.8)198 4.6 (4.3, 4.8)
----------------------------------------------------------------------
        Month 24         192      93.7 (82.2, 106.9)188 4.6 (4.3, 5.0)
----------------------------------------------------------------------
        Month 36         183      93.8 (81.0, 108.6)184 5.1 (4.7, 5.6)
----------------------------------------------------------------------
Anti-HPV 11
----------------------------------------------------------------------
        Month 07         208    696.5 (617.8, 785.2)198 4.1 (4.0, 4.2)
----------------------------------------------------------------------
        Month 24         190      97.1 (84.2, 112.0)188 4.2 (4.0, 4.3)
----------------------------------------------------------------------
        Month 36         174      91.7 (78.3, 107.3)180 4.4 (4.1, 4.7)
----------------------------------------------------------------------
Anti-HPV 16
----------------------------------------------------------------------
        Month 07         193 3889.0 (3318.7, 4557.4)185 6.5 (6.2, 6.9)
----------------------------------------------------------------------
        Month 24         174    393.0 (335.7, 460.1)175 6.8 (6.3, 7.4)
----------------------------------------------------------------------
        Month 36         176    507.3 (434.6, 592.0)170 7.7 (6.8, 8.8)
----------------------------------------------------------------------
Anti-HPV 18
----------------------------------------------------------------------
        Month 07         219    801.2 (693.8, 925.4)209 4.6 (4.3, 5.0)
----------------------------------------------------------------------
        Month 24         204       59.9 (49.7, 72.2)199 4.6 (4.3, 5.0)
----------------------------------------------------------------------
        Month 36         196       59.7 (48.5, 73.5)193 4.8 (4.4, 5.2)
----------------------------------------------------------------------
* The PPI population consisted of individuals who received all 3
 vaccinations within pre-defined day ranges, did not have major
 deviations from the study protocol, met predefined criteria for the
 interval between the Month 6 and Month 7 visit, and were naive (PCR
 negative and seronegative) to the relevant HPV type(s) (Types 6, 11,
 16, and 18) prior to dose 1 and through 1 month Postdose 3 (Month 7).
**Number of subjects randomized to the respective vaccination group
 who received at least 1 injection.
***Number of subjects in the per-protocol analysis with data at the
 specified study time point.
+mMU = milli-Merck units.
Note: These data are from Protocol 007.
----------------------------------------------------------------------


   Table 4 compares anti-HPV GMTs 1 month Postdose 3 among subjects
who received Dose 2 between Month 1 and Month 3 and subjects who
received Dose 3 between Month 4 and Month 8 (Table 4).


                               Table 4
           Summary of GMTs for Variation of Dosing Regimen
----------------------------------------------------------------------

                                   Anti-HPV 6         Anti-HPV 11
                               ---------------------------------------
                                 N       GMT        N       GMT
  Variation of Dosing Regimen          (95% CI)           (95% CI)
======================================================================
Dose 2
----------------------------------------------------------------------
 Early*                                     570.9              824.6
                                883 (542.2, 601.2) 888 (776.7, 875.5)
----------------------------------------------------------------------
 On Time*                                   552.3              739.7
                               1767 (532.3, 573.1)1785 (709.3, 771.5)
----------------------------------------------------------------------
 Late*                                      447.4              613.9
                                313 (405.3, 493.8) 312 (550.8, 684.2)
----------------------------------------------------------------------
Dose 3
----------------------------------------------------------------------
 Early**                                    493.1              658.9
                                495 (460.8, 527.8) 501 (609.5, 712.2)
----------------------------------------------------------------------
 On Time**                                  549.6              752.8
                               2081 (531.1, 568.8)2093 (723.8, 782.9)
----------------------------------------------------------------------
 Late**                                     589.0              865.3
                                335 (537.0, 645.9) 339 (782.6, 956.7)
----------------------------------------------------------------------
*Early = 36 to 50 days Postdose 1; On Time = 51 to 70 days Postdose 1;
 Late = 71 to 84 days Postdose 1.
**Early = 80 to 105 days Postdose 2; On Time = 106 to 137 days
 Postdose 2; Late = 138 to 160 days Postdose 2.
Note: GMT = Geometric mean titer in mMU/mL (mMU = milli-Merck units.)
----------------------------------------------------------------------

                                   Anti-HPV 16         Anti-HPV 18
                             -----------------------------------------
                                N        GMT         N       GMT
 Variation of Dosing Regimen           (95% CI)            (95% CI)
======================================================================
Dose 2
----------------------------------------------------------------------
 Early*                                     2625.3              517.7
                               854 (2415.1, 2853.9) 926 (482.9, 555.0)
----------------------------------------------------------------------
 On Time*                                   2400.0              473.9
                              1737 (2263.9, 2544.3)1894 (451.8, 497.1)
----------------------------------------------------------------------
 Late*                                      1889.7              388.5
                               285 (1624.4, 2198.5) 334 (348.3, 433.3)
----------------------------------------------------------------------
Dose 3
----------------------------------------------------------------------
 Early**                                    2176.6              423.4
                               487 (1953.4, 2425.3) 521 (388.8, 461.2)
----------------------------------------------------------------------
 On Time**                                  2415.0              486.0
                              2015 (2286.3, 2550.9)2214 (464.7, 508.2)
----------------------------------------------------------------------
 Late**                                     2765.9              498.5
                               326 (2408.7, 3176.2) 361 (446.2, 557.0)
----------------------------------------------------------------------
*Early = 36 to 50 days Postdose 1; On Time = 51 to 70 days Postdose 1;
 Late = 71 to 84 days Postdose 1.
**Early = 80 to 105 days Postdose 2; On Time = 106 to 137 days
 Postdose 2; Late = 138 to 160 days Postdose 2.
Note: GMT = Geometric mean titer in mMU/mL (mMU = milli-Merck units.)
----------------------------------------------------------------------


   Bridging the Efficacy of GARDASIL from Young Adult Women to
Adolescent Girls

   A clinical study compared anti-HPV 6, anti-HPV 11, anti-HPV 16,
and anti-HPV 18 GMTs in 10- to 15-year-old girls with responses in 16-
to 23-year-old adolescent and young adult women. Among subjects who
received GARDASIL, 99.1 to 100% became anti-HPV 6, anti-HPV 11,
anti-HPV 16, and anti-HPV 18 seropositive by 1 month Postdose 3.

   Table 5 compares the 1 month Postdose 3 anti-HPV 6, anti-HPV 11,
anti-HPV 16, and anti-HPV 18 GMTs in 9- to 15-year-old girls with
those in 16- to 26-year-old adolescent and young adult women.


                               Table 5
Immunogenicity Bridging Between 9- to 15-year-old Female Adolescents
                  and 16- to 26-year-old Adult Women
----------------------------------------------------------------------
                9- to 15-year-old Female   16- to 26-year-old Adult
                       Adolescents                    Women
                 (Protocols 016 and 018)    (Protocols 013 and 015)
     Assay              N = 1121                    N = 4229
    (cLIA)     -------------------------------------------------------
                n    GMT      (95% CI)      n    GMT      (95% CI)
======================================================================
  Anti-HPV 6   915  928.7   (874.0, 986.8)2631  542.6   (526.2, 559.6)
----------------------------------------------------------------------
  Anti-HPV 11  915 1303.0 (1223.1, 1388.0)2655  761.5   (735.3, 788.6)
----------------------------------------------------------------------
  Anti-HPV 16  913 4909.2 (4547.6, 5299.5)2570 2293.9 (2185.0, 2408.2)
----------------------------------------------------------------------
  Anti-HPV 18  920 1039.8  (964.9, 1120.4)2796  461.6   (444.0, 480.0)
----------------------------------------------------------------------
Note: GMT = Geometric mean titer in mMU/mL (mMU = milli-Merck units).
----------------------------------------------------------------------


   Anti-HPV responses 1 month Postdose 3 among 9- to 15-year-old
girls were non-inferior to anti-HPV responses in 16- to 26-year-old
adolescent and young adult women in the combined database of
immunogenicity studies for GARDASIL.

   On the basis of this immunogenicity bridging, the efficacy of
GARDASIL in 9- to 15-year-old girls is inferred.

   Studies with Other Vaccines

   The safety and immunogenicity of co-administration of GARDASIL
with hepatitis B vaccine (recombinant) (same visit, injections at
separate sites) were evaluated in a randomized study of 1871 women
aged 16 to 24 years at enrollment. Immune response to both hepatitis B
vaccine (recombinant) and GARDASIL was non-inferior whether they were
administered at the same visit or at a different visit.

   INDICATIONS AND USAGE

   GARDASIL is a vaccine indicated in girls and women 9-26 years of
age for the prevention of the following diseases caused by Human
Papillomavirus (HPV) types 6, 11, 16, and 18:

   --  Cervical cancer

   --  Genital warts (condyloma acuminata)

   and the following precancerous or dysplastic lesions:

   --  Cervical adenocarcinoma in situ (AIS)

   --  Cervical intraepithelial neoplasia (CIN) grade 2 and grade 3

   --  Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3

   --  Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3

   --  Cervical intraepithelial neoplasia (CIN) grade 1

   CONTRAINDICATIONS

   Hypersensitivity to the active substances or to any of the
excipients of the vaccine.

   Individuals who develop symptoms indicative of hypersensitivity
after receiving a dose of GARDASIL should not receive further doses of
GARDASIL.

   PRECAUTIONS

   General

   As for any vaccine, vaccination with GARDASIL may not result in
protection in all vaccine recipients.

   * Registered trademark of MERCK & CO., Inc. Whitehouse Station, NJ
08889, USA COPYRIGHT (C) 2006 MERCK & CO., Inc. All rights reserved

   GARDASIL(R)

   (Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18)
Recombinant Vaccine)

   This vaccine is not intended to be used for treatment of active
genital warts; cervical cancer; CIN, VIN, or VaIN.

   This vaccine will not protect against diseases that are not caused
by HPV.

   GARDASIL has not been shown to protect against diseases due to
non-vaccine HPV types.

   As with all injectable vaccines, appropriate medical treatment
should always be readily available in case of rare anaphylactic
reactions following the administration of the vaccine.

   The decision to administer or delay vaccination because of a
current or recent febrile illness depends largely on the severity of
the symptoms and their etiology. Low-grade fever itself and mild upper
respiratory infection are not generally contraindications to
vaccination.

   Individuals with impaired immune responsiveness, whether due to
the use of immunosuppressive therapy, a genetic defect, Human
Immunodeficiency Virus (HIV) infection, or other causes, may have
reduced antibody response to active immunization (see PRECAUTIONS,
Drug Interactions).

   As with other intramuscular injections, GARDASIL should not be
given to individuals with bleeding disorders such as hemophilia or
thrombocytopenia, or to persons on anticoagulant therapy unless the
potential benefits clearly outweigh the risk of administration. If the
decision is made to administer GARDASIL to such persons, it should be
given with steps to avoid the risk of hematoma following the
injection.

   Information for the Patient, Parent, or Guardian

   The health care provider should inform the patient, parent, or
guardian that vaccination does not substitute for routine cervical
cancer screening. Women who receive GARDASIL should continue to
undergo cervical cancer screening per standard of care.

   The health care provider should provide the vaccine information
required to be given with each vaccination to the patient, parent, or
guardian.

   The health care provider should inform the patient, parent, or
guardian of the benefits and risks associated with vaccination. For
risks associated with vaccination, see PRECAUTIONS and ADVERSE
REACTIONS.

   GARDASIL is not recommended for use in pregnant women.

   The health care provider should inform the patient, parent, or
guardian of the importance of completing the immunization series
unless contraindicated.

   Patients, parents, or guardians should be instructed to report any
adverse reactions to their health care provider.

   Drug Interactions

   Use with Other Vaccines

   Results from clinical studies indicate that GARDASIL may be
administered concomitantly (at a separate injection site) with
hepatitis B vaccine (recombinant) (see CLINICAL PHARMACOLOGY, Studies
with Other Vaccines). Co-administration of GARDASIL with other
vaccines has not been studied.

   Use with Hormonal Contraceptives

   In clinical studies, 13,293 subjects (vaccine = 6644; placebo =
6649) who had post-Month 7 follow-up used hormonal contraceptives for
a total of 17,597 person-years (65.1% of the total follow-up time in
the studies). Use of hormonal contraceptives or lack of use of
hormonal contraceptives among study participants did not alter vaccine
efficacy in the PPE population.

   Use with Systemic Immunosuppressive Medications

   Immunosuppressive therapies, including irradiation,
antimetabolites, alkylating agents, cytotoxic drugs, and
corticosteroids (used in greater than physiologic doses), may reduce
the immune responses to vaccines (see PRECAUTIONS, General).

   Carcinogenesis, Mutagenesis, Impairment of Fertility

   GARDASIL has not been evaluated for the potential to cause
carcinogenicity or genotoxicity.

   GARDASIL administered to female rats at a dose of 120 mcg total
protein, which corresponds to approximately 300-fold excess relative
to the projected human dose, had no effects on mating performance,
fertility, or embryonic/fetal survival.

   Pregnancy

   Pregnancy Category B:

   Reproduction studies have been performed in female rats at doses
up to 300 times the human dose (on a mg/kg basis) and have revealed no
evidence of impaired female fertility or harm to the fetus due to
GARDASIL. However, it is not known whether GARDASIL can cause fetal
harm when administered to a pregnant woman or if it can affect
reproductive capacity. GARDASIL should be given to a pregnant woman
only if clearly needed. An evaluation of the effect of GARDASIL on
embryo-fetal, pre- and postweaning development was conducted using
rats. One group of rats was administered GARDASIL twice prior to
gestation, during the period of organogenesis (gestation day 6) and on
lactation day 7. A second group of pregnant rats was administered
GARDASIL during the period of organogenesis (gestation day 6) and on
lactation day 7 only. GARDASIL was administered at 0.5 mL/rat/occasion
(approximately 300-fold excess relative to the projected human dose on
a mg/kg basis) by intramuscular injection. No adverse effects on
mating, fertility, pregnancy, parturition, lactation, embryo-fetal or
pre- and postweaning development were observed. There were no
vaccine-related fetal malformations or other evidence of teratogenesis
noted in this study. In addition, there were no treatment-related
effects on developmental signs, behavior, reproductive performance, or
fertility of the offspring. The effect of GARDASIL on male fertility
has not been studied.

   In clinical studies, women underwent urine pregnancy testing prior
to administration of each dose of GARDASIL. Women who were found to be
pregnant before completion of a 3-dose regimen of GARDASIL were
instructed to defer completion of their vaccination regimen until
resolution of the pregnancy.

   During clinical trials, 2266 women (vaccine = 1115 vs. placebo =
1151) reported at least 1 pregnancy each. Overall, the proportions of
pregnancies with an adverse outcome were comparable in subjects who
received GARDASIL and subjects who received placebo. Overall, 40 and
41 subjects in the group that received GARDASIL or placebo,
respectively (3.6% and 3.6% of all subjects who reported a pregnancy
in the respective vaccination groups), experienced a serious adverse
experience during pregnancy. The most common events reported were
conditions that can result in Caesarean section (e.g., failure of
labor, malpresentation, cephalopelvic disproportion), premature onset
of labor (e.g., threatened abortions, premature rupture of membranes),
and pregnancy-related medical problems (e.g., pre-eclampsia,
hyperemesis). The proportions of pregnant subjects who experienced
such events were comparable between the vaccination groups.

   There were 15 cases of congenital anomaly in pregnancies that
occurred in subjects who received GARDASIL and 16 cases of congenital
anomaly in pregnancies that occurred in subjects who received placebo.

   Further sub-analyses were conducted to evaluate pregnancies with
estimated onset within 30 days or more than 30 days from
administration of a dose of GARDASIL or placebo. For pregnancies with
estimated onset within 30 days of vaccination, 5 cases of congenital
anomaly were observed in the group that received GARDASIL compared to
0 cases of congenital anomaly in the group that received placebo. The
congenital anomalies seen in pregnancies with estimated onset within
30 days of vaccination included pyloric stenosis, congenital
megacolon, congenital hydronephrosis, hip dysplasia and club foot.
Conversely, in pregnancies with onset more than 30 days following
vaccination, 10 cases of congenital anomaly were observed in the group
that received GARDASIL compared with 16 cases of congenital anomaly in
the group that received placebo. The types of anomalies observed were
consistent (regardless of when pregnancy occurred in relation to
vaccination) with those generally observed in pregnancies in women
aged 16 to 26 years.

   Pregnancy Registry for GARDASIL

   Merck & Co., Inc. maintains a Pregnancy Registry to monitor fetal
outcomes of pregnant women exposed to GARDASIL. Patients and health
care providers are encouraged to report any exposure to GARDASIL
during pregnancy by calling [phone].

   Lactation

   It is not known whether vaccine antigens or antibodies induced by
the vaccine are excreted in human milk.

   Because many drugs are excreted in human milk, caution should be
exercised when GARDASIL is administered to a nursing woman.

   A total of 995 nursing mothers (vaccine = 500, placebo = 495) were
given GARDASIL or placebo during the vaccination period of the
clinical trials. GMTs in nursing and non-nursing mothers were as
follows:

   The GMTs in nursing mothers were 595.9 (95% CI: 522.5, 679.5) for
anti-HPV 6, 864.3 (95% CI: 754.0, 990.8) for anti-HPV 11, 3056.9 (95%
CI: 2594.4, 3601.8) for anti-HPV 16, and 527.2 (95% CI: 450.9, 616.5)
for anti-HPV 18. The GMTs for women who did not nurse during vaccine
administration were 540.1 (95% CI: 523.5, 557.2) for anti-HPV 6, 746.3
(95% CI: 720.4, 773.3) for anti-HPV 11, 2290.8 (95% CI: 2180.7,
2406.3) for anti-HPV 16, and 456.0 (95% CI: 438.4, 474.3) for anti-HPV
18.

   Overall, 17 and 9 infants of subjects who received GARDASIL or
placebo, respectively (representing 3.4% and 1.8% of the total number
of subjects who were breast-feeding during the period in which they
received GARDASIL or placebo, respectively), experienced a serious
adverse experience. None was judged by the investigator to be vaccine
related.

   In clinical studies, a higher number of breast-feeding infants (n
= 6) whose mothers received GARDASIL had acute respiratory illnesses
within 30 days post-vaccination of the mother as compared to infants
(n = 2) whose mothers received placebo. In these studies, the rates of
other adverse experiences in the mother and the nursing infant were
comparable between vaccination groups.

   Pediatric Use

   The safety and efficacy of GARDASIL have not been evaluated in
children younger than 9 years.

   Geriatric Use

   The safety and efficacy of GARDASIL have not been evaluated in
adults above the age of 26 years.

   ADVERSE REACTIONS

   In 5 clinical trials (4 placebo-controlled), subjects were
administered GARDASIL or placebo on the day of enrollment, and
approximately 2 and 6 months thereafter. Few subjects (0.1%)
discontinued due to adverse experiences. In all except 1 of the
clinical trials, safety was evaluated using vaccination report card
(VRC)-aided surveillance for 14 days after each injection of GARDASIL
or placebo. The subjects who were monitored using VRC-aided
surveillance included 5088 girls and women 9 through 26 years of age
at enrollment who received GARDASIL and 3790 girls and women who
received placebo.

   Common Adverse Experiences

   Vaccine-related Common Adverse Experiences

   The vaccine-related adverse experiences that were observed among
female recipients of GARDASIL at a frequency of at least 1.0% and also
at a greater frequency than that observed among placebo recipients are
shown in Table 6.



                               Table 6
   Vaccine-related Injection-site and Systemic Adverse Experiences*
----------------------------------------------------------------------
                                            GARDASIL Aluminum- Saline
Adverse Experience                           (N =    ContainingPlacebo
(1 to 5 Days Postvaccination)                 5088)   Placebo   (N =
                                               %    (N = 3470)   320)
                                                         %        %
----------------------------------------------------------------------
  Injection Site
Pain                                           83.9       75.4   48.6
Swelling                                       25.4       15.8    7.3
Erythema                                       24.6       18.4   12.1
Pruritus                                        3.1        2.8    0.6
----------------------------------------------------------------------
                                            GARDASIL     Placebo
Adverse Experience                           (N =       (N = 3790)
(1 to 15 Days Postvaccination)                5088)         %
                                               %
----------------------------------------------------------------------
  Systemic
Fever                                          10.3               8.6
Nausea                                          4.2               4.1
Dizziness                                       2.8               2.6
----------------------------------------------------------------------
* The vaccine-related adverse experiences that were observed among
 recipients of GARDASIL were at a frequency of at least 1.0% and also
 at a greater frequency than that observed among placebo recipients.


   All-cause Common Systemic Adverse Experiences

   All-cause systemic adverse experiences for female subjects that
were observed at a frequency of greater than or equal to 1% where the
incidence in the vaccine group was greater than or equal to the
incidence in the placebo group are shown in Table 7.


                            Table 7
         All-cause Common Systemic Adverse Experiences
----------------------------------------------------------------
Adverse Experience                       GARDASIL     Placebo
(1 to 15 Days Postvaccination)          (N = 5088)   (N = 3790)
                                            %            %
----------------------------------------------------------------
  Pyrexia                                      13.0        11.2
Nausea                                          6.7         6.6
Nasopharyngitis                                 6.4         6.4
Dizziness                                       4.0         3.7
Diarrhea                                        3.6         3.5
Vomiting                                        2.4         1.9
Myalgia                                         2.0         2.0
Cough                                           2.0         1.5
Toothache                                       1.5         1.4
Upper respiratory tract infection               1.5         1.5
Malaise                                         1.4         1.2
Arthralgia                                      1.2         0.9
Insomnia                                        1.2         0.9
Nasal congestion                                1.1         0.9
----------------------------------------------------------------


   Evaluation of Injection-site Adverse Experiences by Dose

   An analysis of injection-site adverse experiences in female
subjects by dose is shown in Table 8. Overall, 94.3% of subjects who
received GARDASIL judged their injection-site adverse experience to be
mild or moderate in intensity.


                               Table 8
      Postdose Evaluation of Injection-site Adverse Experiences
----------------------------------------------------------------------

                                   Vaccine       Aluminum-Containing
                                (% occurrence)          Placebo
                                                    (% occurrence)
======================================================================
           Adverse           Post-Post-Post-Post Post-Post-Post-Post
         Experience          dose dose dose  Any dose dose dose  Any
                               1    2    3  Dose   1    2    3  Dose
----------------------------------------------------------------------
Pain                         63.4 60.7 62.7 83.9 57.0 47.8 49.5 75.4
Mild/Moderate                62.5 59.7 61.2 81.1 56.6 47.3 48.9 74.1
Severe                        0.9  1.0  1.5  2.8  0.4  0.5  0.6  1.3
----------------------------------------------------------------------
Swelling*                    10.2 12.8 15.1 25.4  8.2  7.5  7.6 15.8
Mild/Moderate                 9.6 11.9 14.3 23.3  8.0  7.2  7.3 15.2
Severe                        0.6  0.8  0.8  2.0  0.2  0.3  0.2  0.6
----------------------------------------------------------------------
Erythema*                     9.2 12.1 14.7 24.7  9.8  8.4  8.9 18.4
Mild/Moderate                 9.0 11.7 14.3 23.7  9.5  8.3  8.8 18.0
Severe                        0.2  0.3  0.4  0.9  0.3  0.1  0.1  0.4
----------------------------------------------------------------------
*Intensity of swelling and erythema was measured by size (inches):
 Mild = 0 to
less than or equal to 1; Moderate = greater than 1 to less than or
 equal to 2; Severe = greater than 2.
----------------------------------------------------------------------

                                                     Saline Placebo
                                                     (% occurrence)
======================================================================
                     Adverse                      Post-Post-Post-Post
                   Experience                     dose dose dose  Any
                                                    1    2    3  Dose
----------------------------------------------------------------------
Pain                                              33.7 20.3 27.3 48.6
Mild/Moderate                                     33.3 20.3 27.0 48.0
Severe                                             0.3  0.0  0.3  0.6
----------------------------------------------------------------------
Swelling*                                          4.4  3.0  3.3  7.3
Mild/Moderate                                      4.4  3.0  3.3  7.3
Severe                                             0.0  0.0  0.0  0.0
----------------------------------------------------------------------
Erythema*                                          7.3  5.3  5.7 12.1
Mild/Moderate                                      7.3  5.3  5.7 12.1
Severe                                             0.0  0.0  0.0  0.0
----------------------------------------------------------------------
*Intensity of swelling and erythema was measured by size (inches):
 Mild = 0 to
less than or equal to 1; Moderate = greater than 1 to less than or
 equal to 2; Severe = greater than 2.
----------------------------------------------------------------------

   Evaluation of Fever by Dose

   An analysis of fever in girls and women by dose is shown in Table
9.


                               Table 9
                     Postdose Evaluation of Fever
----------------------------------------------------------------------
                            Vaccine                  Placebo
                        (% occurrence)            (% occurrence)
======================================================================
    Temperature    PostdosePostdose PostdosePostdosePostdose Postdose
         (             1       2        3       1       2        3
    (degree)F)
----------------------------------------------------------------------
 greater than or
  equal to 100 to
   less than 102       3.7      4.1     4.4     3.1      3.8      3.6
----------------------------------------------------------------------
 greater than or
    equal to 102       0.3      0.5     0.5     0.3      0.4      0.6
----------------------------------------------------------------------


   Serious Adverse Experiences

   A total of 102 subjects out of 21,464 total subjects (9- to
26-year-old girls and women and 9- to 15-year-old boys) who received
both GARDASIL and placebo reported a serious adverse experience on Day
1-15 following any vaccination visit during the clinical trials for
GARDASIL. The most frequently reported serious adverse experiences for
GARDASIL compared to placebo and regardless of causality were:

   headache (0.03% GARDASIL vs. 0.02% Placebo),

   gastroenteritis (0.03% GARDASIL vs. 0.01% Placebo),

   appendicitis (0.02% GARDASIL vs. 0.01% Placebo),

   pelvic inflammatory disease (0.02% GARDASIL vs. 0.01% Placebo).

   One case of bronchospasm and 2 cases of asthma were reported as
serious adverse experiences that occurred during Day 1-15 of any
vaccination visit.

   Deaths

   Across the clinical studies, 17 deaths were reported in 21,464
male and female subjects. The events reported were consistent with
events expected in healthy adolescent and adult populations. The most
common cause of death was motor vehicle accident (4 subjects who
received GARDASIL and 3 placebo subjects), followed by
overdose/suicide (1 subject who received GARDASIL and 2 subjects who
received placebo), and pulmonary embolus/deep vein thrombosis (1
subject who received GARDASIL and 1 placebo subject). In addition,
there were 2 cases of sepsis, 1 case of pancreatic cancer, and 1 case
of arrhythmia in the group that received GARDASIL, and 1 case of
asphyxia in the placebo group.

   Systemic Autoimmune Disorders

   In the clinical studies, subjects were evaluated for new medical
conditions that occurred over the course of up to 4 years of follow
up. The number of subjects who received both GARDASIL and placebo and
developed a new medical condition potentially indicative of a systemic
immune disorder is shown in Table 10.


                               Table 10
 Summary of Subjects Who Reported an Incident Condition Potentially
   Indicative of Systemic Autoimmune Disorder After Enrollment in
                     Clinical Trials of GARDASIL
---------------------------------------------------------------------
                                   GARDASIL           Placebo
 Potential Autoimmune Disorder   (N = 11,813)        (N = 9701)
=====================================================================
Specific Terms                       3 (0.025%)            1 (0.010%)
  Juvenile arthritis                         1                     0
  Rheumatoid arthritis                       2                     0
  Systemic lupus erythematosus               0                     1
Other Terms                          6 (0.051%)            2 (0.021%)
  Arthritis                                  5                     2
  Reactive Arthritis                         1                     0
                                               ----------------------
N = Number of subjects enrolled
---------------------------------------------------------------------


   Safety in Concomitant Use with Other Vaccines

   The safety of GARDASIL when administered concomitantly with
hepatitis B vaccine (recombinant) was evaluated in a
placebo-controlled study. There were no statistically significant
higher rates in systemic or injection-site adverse experiences among
subjects who received concomitant vaccination compared with those who
received GARDASIL or hepatitis B vaccine alone.

   Reporting of Adverse Events

   The US Department of Health and Human Services has established a
Vaccine Adverse Event Reporting System (VAERS) to accept all reports
of suspected adverse events after the administration of any vaccine,
including but not limited to the reporting of events required by the
National Childhood Vaccine Injury Act of 1986. For information or a
copy of the vaccine reporting form, call the VAERS toll-free number at
1-800-822-7967 or report on line to www.vaers.hhs.gov.

   DOSAGE AND ADMINISTRATION

   Dosage

   GARDASIL should be administered intramuscularly as 3 separate
0.5-mL doses according to the following schedule:

   First dose: at elected date

   Second dose: 2 months after the first dose

   Third dose: 6 months after the first dose

   Method of Administration

   GARDASIL should be administered intramuscularly in the deltoid
region of the upper arm or in the higher anterolateral area of the
thigh.

   GARDASIL must not be injected intravascularly. Subcutaneous and
intradermal administration have not been studied, and therefore are
not recommended.

   The prefilled syringe is for single use only and should not be
used for more than 1 individual. For single-use vials a separate
sterile syringe and needle must be used for each individual.

   The vaccine should be used as supplied; no dilution or
reconstitution is necessary. The full recommended dose of the vaccine
should be used.

   Shake well before use. Thorough agitation immediately before
administration is necessary to maintain suspension of the vaccine.

   After thorough agitation, GARDASIL is a white, cloudy liquid.
Parenteral drug products should be inspected visually for particulate
matter and discoloration prior to administration. Do not use the
product if particulates are present or if it appears discolored.

   Single-dose Vial Use

   Withdraw the 0.5-mL dose of vaccine from the single-dose vial
using a sterile needle and syringe free of preservatives, antiseptics,
and detergents. Once the single-dose vial has been penetrated, the
withdrawn vaccine should be used promptly, and the vial must be
discarded.

   Prefilled Syringe Use

   Inject the entire contents of the syringe.

   Instructions for using the prefilled single-dose syringes
preassembled with needle guard (safety) device

   (OBJECT OMITTED)

   NOTE: Please use the enclosed needle for administration. If a
different needle is chosen, it should fit securely on the syringe and
be no longer than 1 inch to ensure proper functioning of the needle
guard device. Two detachable labels are provided which can be removed
after the needle is guarded.

   At any of the following steps, avoid contact with the Trigger
Fingers to keep from activating the safety device prematurely.

   Remove Syringe Tip Cap and Needle Cap. Attach Luer Needle by
pressing both Anti-Rotation Tabs to secure syringe and by twisting the
Luer Needle in a clockwise direction until secured to the syringe.
Remove Needle Sheath. Administer injection per standard protocol as
stated above under DOSAGE AND ADMINISTRATION. Depress the Plunger
while grasping the Finger Flange until the entire dose has been given.
The Needle Guard Device will NOT activate to cover and protect the
needle unless the ENTIRE dose has been given. While the Plunger is
still depressed, remove needle from the vaccine recipient. Slowly
release the Plunger and allow syringe to move up until the entire
needle is guarded. For documentation of vaccination, remove detachable
labels by pulling slowly on them. Dispose in approved sharps
container.

   HOW SUPPLIED

   Vials

   No. 4045 -- GARDASIL is supplied as a carton of one 0.5-mL
single-dose vial, NDC 0006-4045-00.

   No. 4045 -- GARDASIL is supplied as a carton of ten 0.5-mL
single-dose vials, NDC 0006-4045-41.

   Syringes

   No. 4109 -- GARDASIL is supplied as a carton of one 0.5-mL
single-dose prefilled Luer Lock syringe, preassembled with UltraSafe
Passive(R)1 delivery system. A one-inch, 25-gauge needle is provided
separately in the package. NDC 0006-4109-31.

   No. 4109 -- GARDASIL is supplied as a carton of six 0.5-mL
single-dose prefilled Luer Lock syringes, preassembled with UltraSafe
Passive(R) delivery system. One-inch, 25-gauge needles are provided
separately in the package. NDC 0006-4109-06.

   Storage

   Store refrigerated at 2 to 8(degree)C (36 to 46(degree)F). Do not
freeze. Protect from light.

   Issued October 2006

   Printed in USA

   (1) UltraSafe Passive(R) delivery system is a Trademark of Safety
Syringes, Inc.
GARDASIL(R)                                                    9682302
(Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18)
Recombinant Vaccine) 9682302



                                 USPPI

                       Patient Information about

                GARDASIL(R) (pronounced "gard-Ah-sill")

  Generic name: (Quadrivalent Human Papillomavirus (Types 6, 11, 16,
                       18) Recombinant Vaccine)

   Read this information with care before you or your child gets
GARDASIL*. You or your child will need 3 doses of the vaccine. It is
important to read this leaflet when you receive each dose. This
leaflet does not take the place of talking with your health care
professional about GARDASIL.

   What is GARDASIL and what is it used for?

   GARDASIL is a vaccine (injection/shot) that helps protect against
the following diseases caused by Human Papillomavirus (HPV) Types in
the vaccine (6, 11, 16, and 18):

   --  Cervical cancer (cancer of the lower end of the uterus or
        womb).

   --  Abnormal and precancerous cervical lesions.

   --  Abnormal and precancerous vaginal lesions.

   --  Abnormal and precancerous vulvar lesions.

   --  Genital warts.

   GARDASIL helps prevent these diseases - but it will not treat
them.

   You or your child cannot get these diseases from GARDASIL.

   What other key information about GARDASIL should I know?

   --  Vaccination does not substitute for routine cervical cancer
        screening. Females who receive GARDASIL should continue
        cervical cancer screening.

   --  As with all vaccines, GARDASIL may not fully protect everyone
        who gets the vaccine.

   --  Gardasil will not protect against diseases due to non-vaccine
        HPV types. There are more than 100 HPV types; GARDASIL helps
        protect against 4 types (6, 11, 16, and 18). These 4 types
        have been selected for GARDASIL because they cause
        approximately 70% of cervical cancers and 90% of genital
        warts.

   --  This vaccine will not protect you against HPV types to which
        you may have already been exposed.

   --  GARDASIL also will not protect against other diseases that are
        not caused by HPV.

   --  GARDASIL works best when given before you or your child has
        any contact with certain types of HPV (i.e., HPV types 6, 11,
        16, and 18).

   Who can receive GARDASIL?

   GARDASIL is for girls and women 9 through 26 years of age.

   See "Who should not receive GARDASIL?" below.

   Who should not receive GARDASIL?

   Anyone who:

   --  is allergic to any of the ingredients in the vaccine. A list
        of ingredients can be found at the end of this leaflet.

   --  has an allergic reaction after getting a dose of the vaccine.

   What should I tell my health care professional before I am
vaccinated or my child is vaccinated with GARDASIL?

   It is very important to tell your health care professional if you
or your child:

   --  has had an allergic reaction to the vaccine.

   --  has a bleeding disorder and cannot receive injections in the
        arm.

   --  has a weakened immune system, for example, due to a genetic
        defect or HIV infection.

   --  is pregnant or is planning to get pregnant. GARDASIL is not
        recommended for use in pregnant women.

   --  has any illness with a fever more than 100(degree)F
        (37.8(degree)C).

   --  takes or plans to take any medicines, even those you can buy
        over the counter.

   Your health care professional will decide if you or your child
should receive the vaccine.

   How is GARDASIL given?

   GARDASIL is given as an injection.

   You or your child will receive 3 doses of the vaccine. Ideally the
doses are given as:

   --  First dose: at a date you and your health care professional
        choose.

   --  Second dose: 2 months after the first dose.

   --  Third dose: 6 months after the first dose.

   Make sure that you or your child gets all 3 doses. This allows you
or your child to get the full benefits of GARDASIL. If you or your
child misses a dose, your health care professional will decide when to
give the missed dose.

   What are the possible side effects of GARDASIL?

   As with all vaccines, there may be some side effects with
GARDASIL. GARDASIL has been shown to be generally well tolerated in
women and girls as young as 9 years of age.

   The most commonly reported side effects included:

   --  pain, swelling, itching, and redness at the injection site.

   --  fever.

   --  nausea.

   --  dizziness.

   Difficulty breathing (bronchospasm) has been reported very rarely.

   If you or your child has any unusual or severe symptoms after
receiving GARDASIL, contact your health care professional right away.

   For a more complete list of side effects, ask your health care
professional.

   What are the ingredients in GARDASIL?

   The main ingredients are purified inactive proteins that come from
HPV Types 6, 11, 16, and 18.

   It also contains amorphous aluminum hydroxyphosphate sulfate,
sodium chloride, L-histidine, polysorbate 80, sodium borate, and water
for injection.

   What are cervical cancer, precancerous lesions, and genital warts?

   Cancer of the cervix is a serious disease that can be
life-threatening. This disease is caused by certain HPV types that can
cause the cells in the lining of the cervix to change from normal to
precancerous lesions. If these are not treated, they can turn
cancerous.

   Genital warts are caused by certain types of HPV. They often
appear as skin-colored growths. They are found on the inside or
outside of the genitals. They can hurt, itch, bleed, and cause
discomfort. These lesions are usually not precancerous. Sometimes, it
takes multiple treatments to eliminate these lesions.

   What is Human Papillomavirus (HPV)?

   HPV is a common virus. In 2005, the Centers for Disease Control
and Prevention (CDC) estimated that 20 million people in the United
States had this virus. There are many different types of HPV; some
cause no harm. Others can cause diseases of the genital area. For most
people the virus goes away on its own. When the virus does not go away
it can develop into cervical cancer, precancerous lesions, or genital
warts, depending on the HPV type. See "What other key information
about GARDASIL should I know?"

   Who is at risk for Human Papillomavirus?

   In 2005, the CDC estimated that at least 50% of sexually active
people catch HPV during their lifetime. A male or female of any age
who takes part in any kind of sexual activity that involves genital
contact is at risk.

   Many people who have HPV may not show any signs or symptoms. This
means that they can pass on the virus to others and not know it.

   Will GARDASIL help me if I already have Human Papillomavirus?

   You may benefit from GARDASIL if you already have HPV. This is
because most people are not infected with all four types of HPV
contained in the vaccine. In clinical trials, individuals with current
or past infection with one or more vaccine-related HPV types prior to
vaccination were protected from disease caused by the remaining
vaccine HPV types. GARDASIL is not intended to be used for treatment
for the above mentioned diseases. Talk to your health care
professional for more information.

   This leaflet is a summary of information about GARDASIL. If you
would like more information, please talk to your health care
professional or visit www.gardasil.com.

   Issued October 2006

   Manufactured and Distributed by: MERCK & CO., Inc.

   Whitehouse Station, NJ 08889, USA

   * Registered trademark of MERCK & CO., Inc. Whitehouse Station, NJ
08889, USA COPYRIGHT (C) 2006 MERCK & CO., Inc. All rights reserved